NO20072713L - Forbindelse omfattende ecteinascidin og et disakkarid - Google Patents

Forbindelse omfattende ecteinascidin og et disakkarid

Info

Publication number
NO20072713L
NO20072713L NO20072713A NO20072713A NO20072713L NO 20072713 L NO20072713 L NO 20072713L NO 20072713 A NO20072713 A NO 20072713A NO 20072713 A NO20072713 A NO 20072713A NO 20072713 L NO20072713 L NO 20072713L
Authority
NO
Norway
Prior art keywords
ecteinascidin
disaccharide
compound
Prior art date
Application number
NO20072713A
Other languages
English (en)
Other versions
NO328035B1 (no
Inventor
Pilar Calvo Salve
Bastiaan Nuijen
Jacob Hendrik Beijnen
Maria Tobio Barreira
Original Assignee
Pharma Mar Sa Soc Unipersonal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35432682&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20072713(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharma Mar Sa Soc Unipersonal filed Critical Pharma Mar Sa Soc Unipersonal
Publication of NO20072713L publication Critical patent/NO20072713L/no
Publication of NO328035B1 publication Critical patent/NO328035B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
NO20072713A 2004-10-29 2007-05-29 Sammensetninger som innbefatter et ecteinascidin og et disakkarid, en fremgangsmate for fremstilling derav, av et beger inneholdende en slik og av en losning for intravenos infusjon, en fremgansgmate for a redusere dannelsen av et ET-701 i en formulering av ET-743, samt anvendelse av losningen. NO328035B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62381304P 2004-10-29 2004-10-29
PCT/GB2005/050184 WO2006046079A1 (en) 2004-10-29 2005-10-12 Formulations comprising ecteinascidin and a disaccharide

Publications (2)

Publication Number Publication Date
NO20072713L true NO20072713L (no) 2007-07-19
NO328035B1 NO328035B1 (no) 2009-11-10

Family

ID=35432682

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072713A NO328035B1 (no) 2004-10-29 2007-05-29 Sammensetninger som innbefatter et ecteinascidin og et disakkarid, en fremgangsmate for fremstilling derav, av et beger inneholdende en slik og av en losning for intravenos infusjon, en fremgansgmate for a redusere dannelsen av et ET-701 i en formulering av ET-743, samt anvendelse av losningen.

Country Status (37)

Country Link
US (2) US8895557B2 (no)
EP (1) EP1658848B1 (no)
JP (1) JP4268163B2 (no)
KR (1) KR101188691B1 (no)
CN (2) CN102018714B (no)
AR (2) AR051653A1 (no)
AT (1) ATE368461T1 (no)
AU (1) AU2005227421B2 (no)
BR (1) BRPI0517238B1 (no)
CA (1) CA2520979C (no)
CY (1) CY1107773T1 (no)
DE (1) DE602005001833T2 (no)
DK (1) DK1658848T3 (no)
ES (1) ES2290844T3 (no)
GT (1) GT200500314A (no)
HK (1) HK1091724A1 (no)
HN (1) HN2005029978A (no)
HR (1) HRP20070374T3 (no)
IL (1) IL182776A (no)
JO (1) JO2464B1 (no)
MX (1) MXPA05011650A (no)
MY (1) MY139049A (no)
NO (1) NO328035B1 (no)
NZ (1) NZ554761A (no)
PA (1) PA8650801A1 (no)
PE (2) PE20060925A1 (no)
PL (1) PL1658848T3 (no)
PT (1) PT1658848E (no)
RS (1) RS50510B (no)
RU (1) RU2382647C2 (no)
SI (1) SI1658848T1 (no)
SV (1) SV2006002283A (no)
TW (1) TWI296523B (no)
UA (1) UA91032C2 (no)
UY (1) UY29183A1 (no)
WO (1) WO2006046079A1 (no)
ZA (1) ZA200703450B (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
DK1365808T3 (da) * 2000-11-06 2011-05-16 Pharma Mar Sa Sammensætninger til antitumorbehandling indeholdende ecteinascidin 743
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
RU2306933C2 (ru) * 2001-10-19 2007-09-27 Фарма Мар, С.А. Улучшенная схема применения противоопухолевого соединения в терапии рака
GB0202544D0 (en) * 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
ATE406897T1 (de) * 2003-11-13 2008-09-15 Pharma Mar Sau Kombination von et-743 mit 5-fluorouracil pro- drugs zur behandlung von krebs
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
EP1691809A1 (en) * 2003-11-14 2006-08-23 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
EP1768671A2 (en) * 2004-07-09 2007-04-04 Pharma Mar, S.A. Use of ecteinascidin in the treatment of cancer in patients with low level of brca1
WO2006035244A2 (en) * 2004-09-29 2006-04-06 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti -inflammatory agents
ATE430586T1 (de) * 2004-10-26 2009-05-15 Pharma Mar Sa Pegyliertes liposomales doxorubicin in kombination mit ecteinescidin 743
DK1658848T3 (da) 2004-10-29 2007-11-26 Pharma Mar Sa Formuleringer omfattende ecteinascidin og et disaccharid
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
JP2011500046A (ja) * 2007-10-19 2011-01-06 ファルマ・マール・ソシエダード・アノニマ Ｅｔ−７４３治療のための予後分子マーカー
US20100196272A1 (en) * 2009-01-30 2010-08-05 Neoprobe Corporation Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran
RS58609B1 (sr) 2010-11-12 2019-05-31 Pharma Mar Sa Kombinovana terapija sa inhibitorom mitoze
JP6042412B2 (ja) * 2011-04-28 2016-12-14 オンコペプティデス エービーＯｎｃｏｐｅｐｔｉｄｅｓ ＡＢ 細胞毒性ジペプチドの凍結乾燥調製物
CN106853252B (zh) * 2015-12-09 2020-03-13 江苏恒瑞医药股份有限公司 曲贝替定药物组合物及其制备方法
CN106880592B (zh) * 2015-12-15 2021-04-06 江苏恒瑞医药股份有限公司 一种曲贝替定的纳米乳及其制备方法
MX2018009088A (es) * 2016-02-04 2018-09-03 Jiangsu Hengrui Medicine Co Composicion farmaceutica inyectable que incluye trabectedina para uso gastrointestinal externo y metodo para la fabricacion de la misma.
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
US20210169873A1 (en) * 2019-10-21 2021-06-10 RK Pharma Solutions LLC Storage-stable ready-to-use injectable formulations of Trabectedin
BR112022009283A2 (pt) * 2019-11-21 2022-08-02 Pharma Mar Sa Métodos de tratamento do câncer do pulmão de células pequenas com formulações de lurbinectedina
EP4041194B1 (en) 2020-04-15 2024-03-13 EVER Valinject GmbH Composition comprising trabectedin and an amino acid
US20230226051A1 (en) 2022-01-20 2023-07-20 Extrovis Ag Trabectedin composition
CN118236331A (zh) * 2022-12-22 2024-06-25 博瑞生物医药（苏州）股份有限公司 一种含卢比替定的药物组合物及其制备方法和应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4537883A (en) 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
AU589282B2 (en) * 1986-06-09 1989-10-05 University Of Illinois Ecteinascidins 729, 743, 745, 759a, 759b and 770
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
DE3635711A1 (de) 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5336669A (en) * 1991-12-10 1994-08-09 Erbamont, Inc. Cyclophosphamide monohydrate and lactose
FR2697752B1 (fr) 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
DE4242863A1 (de) 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
GB9401447D0 (en) 1994-01-26 1994-03-23 Ciba Geigy Ag Pharmaceutical compositions
US20040059112A1 (en) 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
GB9508195D0 (en) 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US5721362A (en) 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
AU7589898A (en) 1997-05-21 1998-12-11 Genentech Inc. Novel administration of thrombopoietin
DE69936845T2 (de) 1998-04-06 2008-05-08 The Board Of Trustees Of The University Of Illinois, Urbana Halbsynthetische ectein-ascidine
EP1077698B1 (en) 1998-05-11 2005-03-02 Pharma Mar, S.A. Metabolites of ecteinascidin 743
JP2000081438A (ja) 1998-06-25 2000-03-21 Sekisui Chem Co Ltd 被験者の癌化学療法による免疫機能低下の測定方法
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
AR035842A1 (es) 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
GB9918178D0 (en) 2000-05-15 1999-10-06 Pharma Mar Sa Synthetic methods
PT1280809E (pt) 2000-04-12 2005-11-30 Pharma Mar Sa Derivados antitumorais de ecteinascidina
US7247892B2 (en) 2000-04-24 2007-07-24 Taylor Geoff W Imaging array utilizing thyristor-based pixel elements
US7420051B2 (en) 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
EP1356097A2 (en) 2000-08-11 2003-10-29 City of Hope The anti-neoplastic agent et-743 inhibits trans activation by sxr
WO2002036145A2 (en) * 2000-10-31 2002-05-10 Pharma Mar, S.A. Kahalalide f formulation
AU2002239565B2 (en) 2000-11-03 2007-11-15 President And Fellows Of Harvard College Saframycins, analogues and uses thereof
DK1365808T3 (da) 2000-11-06 2011-05-16 Pharma Mar Sa Sammensætninger til antitumorbehandling indeholdende ecteinascidin 743
JP2004521122A (ja) 2001-01-25 2004-07-15 ブリストル−マイヤーズ　スクイブ　カンパニー エポチロン類似体の非経口製剤
EP1360337A1 (en) * 2001-02-09 2003-11-12 The Regents Of The University Of California Ecteinascidin family compounds: compositions and methods
WO2002076459A1 (en) 2001-03-06 2002-10-03 Bristol-Myers Squibb Company Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin
AU2002242561A1 (en) 2001-03-30 2002-10-15 Shire Biochem Inc. Methods of treating cancer using cyplastin combined with a dioxolane nucleoside such as troxacitabine
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
RU2306933C2 (ru) * 2001-10-19 2007-09-27 Фарма Мар, С.А. Улучшенная схема применения противоопухолевого соединения в терапии рака
US20040019027A1 (en) * 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0312407D0 (en) 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
ATE406897T1 (de) 2003-11-13 2008-09-15 Pharma Mar Sau Kombination von et-743 mit 5-fluorouracil pro- drugs zur behandlung von krebs
EP1691809A1 (en) 2003-11-14 2006-08-23 Pharma Mar, S.A. Combination therapy comprising the use of et-743 and paclitaxel for treating cancer
GB0326486D0 (en) 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
WO2005118584A2 (en) 2004-05-26 2005-12-15 Axys Pharmaceuticals, Inc. Saframycin analogs as therapeutic agents in the treatment of cancer
EP1768671A2 (en) 2004-07-09 2007-04-04 Pharma Mar, S.A. Use of ecteinascidin in the treatment of cancer in patients with low level of brca1
WO2006035244A2 (en) 2004-09-29 2006-04-06 Pharma Mar S.A., Sociedad Unipersonal Ecteinascidin compounds as anti -inflammatory agents
ATE430586T1 (de) 2004-10-26 2009-05-15 Pharma Mar Sa Pegyliertes liposomales doxorubicin in kombination mit ecteinescidin 743
DK1658848T3 (da) 2004-10-29 2007-11-26 Pharma Mar Sa Formuleringer omfattende ecteinascidin og et disaccharid
WO2006066183A2 (en) 2004-12-16 2006-06-22 Axys Pharmaceuticals, Inc. Novel saframycin analogs as therapeutic agents
JP2009517403A (ja) 2005-11-25 2009-04-30 ユニバーシティー オブ メディシン アンド デンティストリー オブ ニュージャージー Ｐａｒｐ−１阻害剤の使用
US20100009906A1 (en) 2006-05-12 2010-01-14 Pharma Mar, S.A. Anticancer Treatments

Also Published As

Publication number Publication date
PA8650801A1 (es) 2006-09-22
HRP20070374T3 (en) 2007-10-31
PL1658848T3 (pl) 2007-12-31
PE20100089A1 (es) 2010-03-01
EP1658848A1 (en) 2006-05-24
AU2005227421A1 (en) 2006-05-18
CA2520979C (en) 2009-03-24
UY29183A1 (es) 2006-05-31
NZ554761A (en) 2010-01-29
ATE368461T1 (de) 2007-08-15
RU2382647C2 (ru) 2010-02-27
JP4268163B2 (ja) 2009-05-27
BRPI0517238B1 (pt) 2021-11-09
SV2006002283A (es) 2006-07-20
CN102018714A (zh) 2011-04-20
AR110986A2 (es) 2019-05-22
WO2006046079A1 (en) 2006-05-04
UA91032C2 (en) 2010-06-25
ZA200703450B (en) 2008-09-25
TWI296523B (en) 2008-05-11
TW200621256A (en) 2006-07-01
JO2464B1 (en) 2009-01-20
JP2006124393A (ja) 2006-05-18
HK1091724A1 (en) 2007-01-26
HN2005029978A (es) 2009-10-27
IL182776A (en) 2010-06-30
US10322183B2 (en) 2019-06-18
CY1107773T1 (el) 2013-06-19
US8895557B2 (en) 2014-11-25
KR101188691B1 (ko) 2012-10-09
PE20060925A1 (es) 2006-10-23
BRPI0517238A (pt) 2008-10-07
PT1658848E (pt) 2007-11-05
KR20070091121A (ko) 2007-09-07
NO328035B1 (no) 2009-11-10
MY139049A (en) 2009-08-28
RU2007119724A (ru) 2008-12-10
AU2005227421B2 (en) 2007-06-28
EP1658848B1 (en) 2007-08-01
CN102018714B (zh) 2014-01-08
DE602005001833T2 (de) 2008-04-17
ES2290844T3 (es) 2008-02-16
US20150094313A1 (en) 2015-04-02
SI1658848T1 (sl) 2007-12-31
IL182776A0 (en) 2007-08-19
CN1823794A (zh) 2006-08-30
RS50510B (sr) 2010-03-02
AR051653A1 (es) 2007-01-31
CA2520979A1 (en) 2006-02-15
MXPA05011650A (es) 2006-05-17
US20060094687A1 (en) 2006-05-04
DE602005001833D1 (de) 2007-09-13
DK1658848T3 (da) 2007-11-26
GT200500314A (es) 2007-03-22

Similar Documents

Publication Publication Date Title
NO20072713L (no) Forbindelse omfattende ecteinascidin og et disakkarid
NL301229I2 (nl) Deoxycholaat
NO2017017I1 (no) umeklinidium og vilanterol
DE602004026114D1 (de) Verweilnadel
DK1755713T3 (da) Injektionsindretning
DK1704844T3 (da) Automatisk administrationsapparat og lægemiddeltilførselsapparat
DK1771421T3 (da) N-hydroxyamidderivater og anvendelse deraf
NO2016020I2 (no) Imidacloprid og Flumetrin
DK1829874T3 (da) Tricyklisk forbindelse og anvendelse deraf
DK1885716T3 (da) Thiazolderivater og anvendelse deraf
DE502005002500D1 (de) Fördervorrichtung
DK3078274T3 (da) Sporelementer
DE502005001451D1 (de) Fugenabdeckprofil
FI20041057A0 (fi) Pelkistysainekoostumus
DE602005014339D1 (de) Ür
NO20053856D0 (no) Bronn og skjot.
FR2876140B1 (fr) Portail a battants
FR2879415B1 (fr) Epingle a chignon
ITMI20050793A1 (it) Attrezzo sportivo-pubblicitario e per gioco a formasferica
FR2868113B1 (fr) Fenetre
FR2873153B1 (fr) Volet roulant
AT501079B1 (de) Türe
NO20044457D0 (no) Kombi-Brodd og Kombi-Brodd-System for Rollotorer
SE0400213D0 (sv) Diurea Derivatives
ITLC20040003A1 (it) C.A.R. e S.A.E.